Joint research paper with Josai University Faculty of Pharmaceutical Sciences has been published in “Frontiers in Drug Delivery”. (2023.04.04)

We are pleased to announce that a joint research paper by Josai University Faculty of Pharmaceutical Sciences and atDose using the “atDose Core”, an ultra small amount localized drug delivery device, has been published in “Frontiers in Drug Delivery”, a journal specializing in drug delivery systems, in April 2023.

For more information on the paper, please click on the link below.
https://www.frontiersin.org/articles/10.3389/fddev.2023.1150894/full

The title of the article published in Frontiers in Drug Delivery is “Usefulness of direct intratumoral administration of doxorubicin hydrochloride with an electro-osmosis-assisted pump”. This is a study of the effectiveness of local administration of very small amounts of anticancer drugs to the affected area of cancer using the “atDose Core”, an ultra-small amount, topical dosing device by atDose.

In this study, the anticancer drug “doxorubicin hydrochloride” was administered to a model-rat of breast cancer. As a result, it was confirmed that locallzed and very small amounts administered using the EO pump reduced side effects while maintaining the efficacy of the anticancer drug in reducing tumor volume, compared to conventional systemic administration.

We have started a joint research with Professor Hiroaki Todo of the Department of Pharmacokinetics and Pharmacodynamics, Josai University Faculty of Pharmacy and Pharmaceutical Sciences in 2019 on the effect of local administration on reducing the side effects of anticancer drugs. We will continue this research and continue to realise the launch of “atDose Core”.

Thanks to all parties collaborating on this study.
We also thank Frontiers officials for their assistance in peer review and publication.

Hidenori Nakamura
Founder & CEO of atDose Co., Ltd.